Electrification in life sciences is emerging as a strategic imperative beyond mere carbon reduction. New research reveals it ...
StockStory.org on MSN
Gilead Sciences (GILD): Buy, sell, or hold post Q2 earnings?
Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark ...
Wave Life Sciences (WVE) stock analysis: low valuation (2.45x cash, no debt) vs. RNA therapy competition; key upside tied to WVE-N531 results. See more here.
Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders. The ...
Life sciences organisations generate data at extraordinary speed, but insight remains slow. Semantic knowledge graphs and ontologies address this by providing context and structur ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results